USPTO serial 88530588
BIOSYNTH CARBOSYNTH
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 3, 2020
- Examiner
- MOLINOFF, JEFFREY S.
- Law office
- Historical data usage
What this means
Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.
Need help with BIOSYNTH CARBOSYNTH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Tara Sliva
Tara Sliva DENTONS US LLPP.O. Box 1302CHICAGO, IL 60604United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemicals and organic chemicals used as enzyme substrates, enzyme inducers, namely, aminoglutethimides, carbamazepines, griseofulvins, and primidones, enzyme inactivators, or cultural medium additives for use in the field of microbiology and molecular biology; biochemical and organic chemical reagents for clinical diagnostic laboratory use; biochemical and organic chemicals for use in the manufacture of pharmaceuticals and cosmetics; Chemical reagents for medical research use in the field of immunology; Chemical reagents for medical laboratory analysis purposes, namely, for use as a routine medical supplement to blood culture media in vitro to inhibit blood coagulation and to improve the detection limits for individual microorganisms | ACTIVE | Jul 1, 2019 |
| 005 | Medicinal preparations, namely, photosensitizing agents used as a dermatologic drug for the treatment of skin cancer by phototherapy; Chemical reagents for medical or veterinarian use; Chemical reagents for use as culture media for cultures of microorganisms for medical use, namely, for the isolation and identification of the bacteria strain Escherichia coli O157:H7; Chemical preparations for medical purposes, namely, for Cholesterol testing to prevent possible consequences of Hypercholesterolemia such as atherosclerosis, coronary heart disease and other forms of cardiovascular diseases; Chemical preparations for medical purposes, namely, for novel enzyme responsive inhibitors that allow for modifications of the composition of microbial communities; Organic chemical preparations for medical purposes, namely, immunomodulators with anti-inflammatory properties; Organic chemical preparations and enzymes for medical laboratory analysis purposes, namely, for medical detection, identification and quantification of strains of pathogenic bacteria; Chemical preparations for medical laboratory analysis purposes, namely, for medical immunological and microbiological blood testing; Chemical preparations for medical laboratory analysis purposes, namely, for medical detection of pathogenic bacteria, namely, various strains of Listeria, Clostridium, Bacillus and Staphylococcus; Chemical preparations for medical laboratory analysis purposes, namely, for the medical detection and quantification of bacteria strains of Escherichia coli; Medical preparations for the diagnosis of Staphylococus aureus, in particular for Methicillin-resistant Staphylococcus aureus (MRSA) | ACTIVE | Jul 1, 2019 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 27, 2026 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Jan 27, 2026 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Jan 27, 2026 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Jan 22, 2026 | PR23 | POST REGISTRATION ACTION MAILED - SEC. 8 & 15 | — |
| Jan 22, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 20, 2025 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Mar 3, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Aug 18, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 18, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 18, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 3, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 17, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 17, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 27, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 7, 2019 | ALIE | ASSIGNED TO LIE | — |
| Nov 4, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 31, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 30, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 30, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 5, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 5, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 5, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 5, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 31, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 26, 2019 | NWAP | NEW APPLICATION ENTERED | — |